Use of Behavior Change Techniques and Quality of Commercially Available Inflammatory Bowel Disease Apps

Noser, Amy E.; Lancaster, Brittany; Hommel, Kevin A.; Roberts, Caroline M.; King, Jessica; Alt, Elizabeth; Fredericks, Emily M.; Ramsey, Rachelle R.

doi:10.1007/s10620-023-07884-7

Cited by 4 publications

(2 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…My IBD Care: Crohn’s and Colitis was rated as a high-quality mHealth app to support self-management of mental health; however, it was less comprehensive than Lyfe MD because it did not offer diet therapy. Our findings were supported by a recent study evaluating the quality of commercially available IBD-related apps, 25 which similarly used the MARS to rate the overall quality of the reviewed mHealth apps. That study identified very similar overall quality scores for the My IBD Care: Crohn’s and Colitis app (overall quality rating 4.62) as well as the IBD Fighter app (overall quality rating 3.36), supporting our findings in the current study, although the Lyfe MD app was not reviewed in that recent manuscript.…”

Section: Discussionsupporting

confidence: 82%

Identification and Evaluation of Mobile Applications for Self-Management of Diet and Lifestyle for Patients with Inflammatory Bowel Disease

Gold,

Chiew,

Rajagopalan

et al. 2023

Journal of the Canadian Association of Gastroenterology

View full text Add to dashboard Cite

Background Mobile health applications (apps) providing diet and lifestyle self-management programs to patients with inflammatory bowel disease (IBD) are emerging. The objective of this study was to evaluate current apps available in the US and Canada based on app quality, perceived impact on diet and mental health and comprehensiveness to support self-management. Methods The Apple iOS and Google Play app stores were searched for terms related to IBD. Apps were included if they targeted diet and lifestyle behaviours for patients living with IBD and were available to the general public. Apps were excluded if they were not specific to IBD, not available in English, did not target diet or lifestyle therapy, were not available in the US and Canada, or did not offer stand-alone self-management programs. The Mobile App Rating Scale was used to assess mobile app quality. Results A total of 1,512 apps were identified through the app stores. Six apps met inclusion criteria. My IBD Care: Crohn’s and Colitis received the highest quality rating and LyfeMD received the highest overall app rating. Only these two apps provided behaviour tracking over time, and three (50 percent) apps provided good-quality information. Conclusions While many IBD-related apps exist, few support self-management of diet and lifestyle behaviours. The My IBD Care and LyfeMD apps had the highest ratings and can be used to track lifestyle behaviours. The effectiveness of these apps to improve behaviours, and subsequently impact the disease course and quality of life, should be explored in future studies.

show abstract

Section: Discussionsupporting

confidence: 82%

Identification and Evaluation of Mobile Applications for Self-Management of Diet and Lifestyle for Patients with Inflammatory Bowel Disease

Gold,

Chiew,

Rajagopalan

et al. 2023

Journal of the Canadian Association of Gastroenterology

View full text Add to dashboard Cite

show abstract

“…The novelty of the study design is the optional inclusion of 2 innovative wearables, which could provide a new layer of patient-derived data. Correlations with disease activity and QoL have been established before [6][7][8], but the cohort sizes were small and not in a longitudinal setting around targeted therapy. Therefore, real-world studies to assess the effect of digital health tools on disease activity are still needed [9].…”

Section: Introductionmentioning

confidence: 99%

Health Status, Quality of Life, Psychosocial Well-being, and Wearables Data of Patients With Active Ulcerative Colitis Receiving Filgotinib Therapy (FilgoColitis Study): Protocol for a Real-world Observational Study

Plachta-Danielzik,

Grasskemper,

Schmidt

et al. 2023

JMIR Res Protoc

View full text Add to dashboard Cite

Background Filgotinib was approved in Germany for treating patients with moderate to severe active ulcerative colitis in November 2021. It represents a preferential Janus kinase 1 inhibitor. The FilgoColitis study began recruiting immediately after approval and aims to assess filgotinib effectiveness under real-world conditions with a particular focus on patient-reported outcomes (PROs). The novelty of the study design is the optional inclusion of 2 innovative wearables, which could provide a new layer of patient-derived data. Objective The study investigates quality of life (QoL) and psychosocial well-being of patients with active ulcerative colitis during long-term exposure to filgotinib. PROs related to QoL and psychometric profiles (fatigue and depression) are collected alongside with disease activity symptom scores. We aim to evaluate physical activity patterns collected by wearables as an addition to traditional PROs, patient-reported health status, and QoL in different phases of disease activity. Methods This is a prospective, single-arm, multicentric, noninterventional, observational study with a sample size of 250 patients. QoL is assessed with validated questionnaires: the Short Inflammatory Bowel Disease Questionnaire (sIBDQ) for the disease-specific QoL, the EQ-5D for the general QoL, and the fatigue questionnaire (Inflammatory Bowel Disease-Fatigue [IBD-F]). Physical activity data are collected from patients using wearables (SENS motion leg sensor [accelerometry] and smartwatch, GARMIN vívosmart 4). Results The enrollment started in December 2021 and was still open at the date of submission. After 6 months of study initiation, 69 patients were enrolled. The study is expected to be completed in June 2026. Conclusions Real-world data for novel drugs are important to assess effectiveness outside of highly selected populations represented by randomized controlled trials. We examine whether patients’ QoL and other PROs can be supplemented with physical activity patterns measured objectively. Use of wearables with newly defined outcomes represents an additional observational tool for monitoring disease activity in patients with inflammatory bowel disease. Trial Registration German Clinical Trials Register DRKS00027327; https://drks.de/search/en/trial/DRKS00027327 International Registered Report Identifier (IRRID) DERR1-10.2196/42574

show abstract

Development and Validation of a Mobile-Centered Digital Health Readiness Scale (mDiHERS): Health Literacy and Equity Scale

Kim,

Schnall,

Yoon

et al. 2024

J Med Internet Res

View full text Add to dashboard Cite

Background There has been a rapid expansion of digital health care services, making the need for measuring and improving digital health readiness a priority. In response, our study team developed the Mobile-Centered Digital Health Readiness: Health Literacy and Equity Scale (mDiHERS) to measure digital health readiness. Objective We aim to develop and validate a scale that assesses digital health readiness, encompassing literacy and equity, and to ensure the effective use of mobile-centered digital health services. Methods This study was conducted from October 2021 to October 2022 to develop and validate the mDiHERS. Participants included patients with inflammatory bowel disease, which is a chronic condition requiring continuous management, and experts in medical and nursing informatics. The scale development involved a literature review, focus group interviews, and content validity evaluations. A total of 440 patients with inflammatory bowel disease were recruited for the validation phase, with 403 completing the survey. The scale’s validity and reliability were assessed through exploratory factor analysis and Cronbach α. The scale was translated into English by translators and bilingual and native researchers, ensuring its applicability in diverse settings. Results The mDiHERS consists of 36 items across 6 domains, with a 5-point Likert scale for responses. The validation process confirmed the scale’s construct validity, with 4 factors explaining 65.05% of the total variance. The scale’s reliability was established with Cronbach α values ranging from 0.84 to 0.91. The scale’s development considered the technical proficiency necessary for engaging with health mobile apps and devices, reflecting the importance of subjective confidence and objective skills in digital health literacy. Conclusions The mDiHERS is a validated tool for measuring patients’ readiness and ability to use digital health services. The mDiHERS assesses user characteristics, digital accessibility, literacy, and equity to contribute to the effective use of digital health services and improve accessibility. The development and validation of the mDiHERS emphasize the importance of confidence and competence in managing health digitally. Continuous improvements are necessary to ensure that all patients can benefit from digital health care.

show abstract

Use of Behavior Change Techniques and Quality of Commercially Available Inflammatory Bowel Disease Apps

Cited by 4 publications

References 38 publications

Identification and Evaluation of Mobile Applications for Self-Management of Diet and Lifestyle for Patients with Inflammatory Bowel Disease

Identification and Evaluation of Mobile Applications for Self-Management of Diet and Lifestyle for Patients with Inflammatory Bowel Disease

Health Status, Quality of Life, Psychosocial Well-being, and Wearables Data of Patients With Active Ulcerative Colitis Receiving Filgotinib Therapy (FilgoColitis Study): Protocol for a Real-world Observational Study

Development and Validation of a Mobile-Centered Digital Health Readiness Scale (mDiHERS): Health Literacy and Equity Scale

Contact Info

Product

Resources

About